^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PTK7-targeted antibody-drug conjugate

    Related drugs:
    4d
    An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, AbbVie | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    PTK7 (Protein Tyrosine Kinase 7)
    |
    cofetuzumab pelidotin (ABBV-647)
    24d
    A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors (clinicaltrials.gov)
    P2, N=290, Not yet recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    New P2 trial
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab) • carboplatin
    25d
    Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=226, Recruiting, Whitehawk Therapeutics, Inc.
    New P1 trial • First-in-human
    |
    EGFR (Epidermal growth factor receptor)
    1m
    J6D-MC-JSDA: A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors. (2025-521916-20-00)
    P1, N=80, Recruiting, Eli Lilly & Co.
    New P1 trial
    2ms
    KIVU-107-01: A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=76, Recruiting, Kivu Bioscience Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    4ms
    A Study of SKB518 in Patients With Lung Cancer (clinicaltrials.gov)
    P2, N=192, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | N=80 --> 192 | Trial completion date: Jun 2027 --> Oct 2027 | Trial primary completion date: Jun 2027 --> Feb 2027
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    carboplatin • Tevimbra (tislelizumab-jsgr)
    4ms
    A Study of SKB518 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    4ms
    A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=76, Not yet recruiting, Kivu Bioscience Inc.
    New P1 trial
    6ms
    Expression of antibody-drug conjugate targets in soft tissue sarcomas. (PubMed, ESMO Open)
    STSs express multiple target genes relevant for ADC treatment and expression varies between and within the pathological types. This comprehensive ADC target landscape, based on the largest molecular epidemiology study in STS, should help clinicians and drug developers for further evaluation of ADCs across STS types.
    Journal • PARP Biomarker • IO biomarker
    |
    PTK7 (Protein Tyrosine Kinase 7)
    6ms
    A Study of LY4175408 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=240, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    6ms
    PRO1107 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=33, Terminated, Genmab | Trial completion date: Jun 2028 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2028 --> Aug 2025; Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation
    Trial completion date • Trial termination • Trial primary completion date
    8ms
    PRO1107 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=42, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=280 --> 42
    Enrollment closed • Enrollment change